Will Johnson & Johnson Remain A Top Dividend Aristocrat Stock Going Forward?


  • At the end of 2023, Johnson & Johnson will be spinning off its Consumer Health segment.
  • Consumer Health has been the backbone of the company, but the Pharmaceutical and MedTech segments have provided the growth.
  • Given the uncertainty surrounding the U.S. economy, healthcare is a defensive sector to invest.
Sealed Bottle of Extra Strength Tylenol Caplets with Box

skhoward/iStock Unreleased via Getty Images

Johnson and Johnson (NYSE:JNJ) has been in the news lately, largely for reasons they prefer not to have. For context, Johnson & Johnson has been served with thousands of potential lawsuits regarding talc issues within their once-popular Johnson’s Baby Powder. The lawsuits claimed that the

Disclosure: I/we have a beneficial long position in the shares of JNJ, ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Historic Market Opportunity! Act Now!

The recent market crash has created exceptional opportunities. Many high-quality REITs are now offered at >10% sustainable dividend yields and have 100-200% upside potential in a recovery.

At High Yield Landlord, we are loading up on these discounted opportunities and share all our Top Ideas with our 1,500 members in real-time.

Start your 2-Week Free Trial today and get instant access to all our Top Picks, 3 Model Portfolios, Course to REIT investing, Tracking tools, and much more.

We have limited spots at a 20% discount. Get Started Today!

Leave a Reply

Your email address will not be published. Required fields are marked *